Daily PubMed evidence board
Resection quality and oncologic outcomes after robotic versus laparoscopic total mesorectal excision for mid and low rectal cancer: a systematic review and meta-analysis of randomised trials.
This systematic review and meta-analysis combined data from randomized trials comparing robotic and laparoscopic total mesorectal excision (TME) for mid a…
Signal score64Research triage score
CertaintyModerateVerify in full text
PMID42223567Source identifier
Research triage, not medical advice
Do not use this summary, score, or benefit-cost estimate to diagnose, treat, prescribe, or change care without reviewing the full study and consulting qualified professionals.
Verify before acting
Check full-text methods, eligibility, outcomes, risk of bias, harms, conflicts, funding, replication, and applicability.
Plain-English signal
This systematic review and meta-analysis combined data from randomized trials comparing robotic and laparoscopic total mesorectal excision (TME) for mid and low rectal cancer. The pooled results reported that robotic TME had lower rates of positive circumferential resection margins and higher rates of complete mesorectal excision compared with laparoscopic TME. Robotic surgery also had fewer conversions to open surgery. Early safety (intraoperative and early postoperative complications) was similar between approaches. Two trials reported three-year outcomes suggesting fewer locoregional recurrences and a modest improvement in disease-free survival with robotics, but overall survival was not different. The abstract-level findings suggest improved pathological resection quality with robotics, but the full text should be reviewed before changing practice.
Why it matters
- TME resection quality (CRM positivity and mesorectal completeness) strongly influences local control and survival in mid and low rectal cancer-this study pools randomized evidence comparing robotic versus laparoscopic approaches on those pathologic quality metrics.
- If robotic TME reliably reduces CRM positivity and increases completeness, it could affect surgical approach recommendations, training priorities, and resource allocation for rectal cancer surgery.
- The meta-analysis also reports early oncologic outcomes (three-year locoregional recurrence and disease-free survival) from randomized data, which are more decision-relevant than single-center observational series.
Primary outcomes
- Circumferential resection margin (CRM) positivity
- Completeness of the mesorectum (complete TME)
Effect summary
From abstract-pooled randomized data (4 trials, 1,952 patients): robotic TME reduced CRM positivity (OR 0.58, 95% CI 0.38-0.87) and increased complete TME rates (OR 1.55, 95% CI 1.14-2.12). Conversion to open surgery was less frequent with robotics (OR 0.41, 95% CI 0.21-0.79). Intraoperative and early postoperative complication rates were similar. Two trials reported three-year outcomes: robotic TME had lower locoregional recurrence (OR 0.43, 95% CI 0.23-0.81) and a modest improvement in disease-free survival (HR 0.78, 95% CI 0.61-0.99); overall survival did not differ (HR 0.79, 95% CI 0.57-1.11). Abstract notes low event rates for oncologic endpoints; interpret cautiously.
Benefit-cost lens
| Quick take | Robotic TME showed better pathological resection quality and lower conversion rates versus laparoscopy in randomized trials; claims about long-term patient benefit or cost-effectiveness require absolute event rates, local costs, and implementation assumptions. |
|---|---|
| BCR anchor | 2 |
| Time horizon | 3 |
| Discount rate | 0.03 |
| Assumptions | Assessment based on PubMed metadata and abstract only; full text needed to verify methods, exact absolute event counts, follow-up completeness, and subgroup effects. |
Benefit-cost fields are assumptions-based unless explicitly source-derived. Treat them as prompts for deeper economic review.
Risk of bias
| Tool | rapid-abstract-screen |
|---|---|
| Verdict | Some concerns |
| Notes | Assessment based only on PubMed metadata and abstract. Although the study pools randomized trials, the abstract does not provide trial-level risk-of-bias details (allocation concealment, blinding, attrition), heterogeneity measures, or full outcome ascertainment-full-text appraisal needed. |
Harms, equity, conflicts & implementation
| Implementation | Full-text review, verification of absolute effect sizes, local baseline rates, capital and operating costs for robotic systems, surgeon training and credentialing needs, and modeling of downstream oncologic benefits before policy or practice change. |
|---|---|
| Equity impact | Unclear from abstract. Access to robotic platforms and surgeon experience likely vary by region and center; potential equity concerns if benefits require high-volume centers or costly equipment. |
| Harms | No clear differences in intraoperative or early postoperative complications reported in the abstract. Full-text review needed to assess other harms, longer-term functional outcomes (e.g., bowel, urinary, sexual function), and adverse events related to conversions or reoperations. |
| Replication | Unknown from abstract-level triage; replication would require independent analysis of full-text trial data. |
Source links — verify original
Use PubMed and full-text links to confirm methods, population, outcomes, harms, conflicts, and applicability.